7-[(1R,2R,3R,5S)-3-[tert-Butyl(Dimethyl)Silyl]Oxy-2-[(E,3S)-3-[tert-Butyl(Dimethyl)Silyl]Oxyoct-1-Enyl]-5-Hydroxycyclopentyl]Heptanoic Acid置于氢氟酸,水体系中,用 乙腈 作为反应溶剂,化学反应 6.0H,以90%的收率获得产物前列地尔 参考文献:The Meyer-schuster Rearrangement: A New Synthetic Strategy Leading To Prostaglandins And Their Drug Analogs,Bimatoprost And Latanoprost 标题:The Meyer-schuster Rearrangement: A New Synthetic Strategy Leading To Prostaglandins And Their Drug Analogs,Bimatoprost And Latanoprost 摘要:Gold(I) Mediated Meyer Schuster Rearrangement For The Installation Of The 'Lower' Side Chain Of Prostaglandins And Their Analogs Has Been Developed. This Au-Mediated Rearrangement,Featuring A Low Catalyst Loading And Mild Reaction Conditions,Has Been Demonstrated To Be An Efficient Alternative To The Standard Horner-Wadsworth-Emmons Reaction In Prostaglandin Chemistry. Moreover,The Present Results Provide A New Synthetic Process Leading To Pharmacologically Active Prostanoids: Latanoprost And Bimatoprost,That Continue To Hold Key Positions In The Anti-Glaucoma Drug Market. (C) 2010 Elsevier Ltd. All Rights Reserved. DOI:10.1016/j.Tet.2010.07.069
专利号:US-6350595-B1 优先权日:1997-10-28 标题:Synthesis of polynucleotides having random sequences 发明人:NEUNER PHILIPPE 权利人:ISTITUTO DI RICERCHE DI MOLECO 摘要:Subject of this invention is a process for the chemical synthesis of polynucleotides having totally or partially random sequences, based on the utilization, as synthesis monomer units for the random sequence part, or presynthesized mononucleotides and dinucleotides. Said synthesis is carried out on separate supports, so that on each of those supports is alternated at least one reaction cycle wherein a mixture of said dinucleotides is bound, with at least one reaction cycle wherein a mononucleotide is bound, and that in a preferred embodiment at the end of the n cycles required for a codon synthesis, the supports are mixed and then redivided into one or more reaction containers. The resulting polynucleotides are such that, for the random sequence part, each trinucleotide unit is fit to match only a limited number of codons, predefined for each unity in number and sequence, and the genetic code degeneracy effects can thus be eliminated. FIG. 1 shows the chemical structure of the dinucleotides utilized as monomer units for the synthesis of codons forming the final sequence.
专利号:US-3992413-A 优先权日:1975-07-25 标 题 :Intermediates in the synthesis of prostaglandins 发明人:TAUB DAVID; WENDLER NORMAN L 权利人:MERCK & CO INC 摘要:The invention relates to a new and novel synthesis of prostaglandin E 2 , and it particularly relates to a novel process starting with relatively inexpensive starting materials. The invention further relates to a synthesis which is readily adaptable for large scale processing because of the high yields in the individual reaction steps. n The invention further relates to novel compounds formed as intermediates in the synthesis of prostaglandin E 2 . The invention still further relates to synthetic analogs and known metabolites of prostaglandin E 2 and prostaglandin E 1 , useful as standards in certain biological assays for determining prostaglandin-like activity.
专利号:US-3992439-A 优先权日:1972-04-17 标 题:Synthesis of prostaglandins of the 'one'-series 发明人:SCHAAF THOMAS K; COREY ELIAS J 权利人:PFIZER 摘要:In the synthesis of prostaglandins of the 'one' -series an alteration in the conventional reaction sequence avoids side reactions and provides an improved synthesis via a series of novel intermediates. In this improved synthesis the side chain at the 8 position is attached to the five membered ring before the side chain at the 12 position is attached.
专利号:US-5545568-A 优先权日:1992-09-14 标题:Solid phase and combinatorial synthesis of compounds on a solid support 发明人:ELLMAN JONATHAN A 权利人:UNIV CALIFORNIA 摘要:Methods, compositions, and devices for synthesizing combinatorial libraries of various useful compounds, such as benzodiazepines, prostaglandins, β-turn mimetics and glycerol-derived drugs is described. In order to expediently synthesize such combinatorial libraries of derivatives based upon these core structures, a general methodology for the solid phase synthesis of these derivatives is also provided. This disclosure thus also describes an important extension of solid phase synthesis methods to nonpolymeric organic compounds.
专利号:US-4214099-A 优先权日:1973-10-24 标题:Intermediates for synthesis of precursors for prostaglandins 发明人:BINDRA JASJIT S; COREY ELIAS J; SCHAAF THOMAS K 权利人:PFIZER 摘要:A new synthesis of key prostaglandin precursors and intermediates employed in their preparation. The novel synthetic sequence of this invention is shorter and more efficient than those previously employed to prepare to key intermediate.
专利号:US-4204999-A 优先权日:1976-02-20 标题:Process for making bicyclic lactone derivatives for use as intermediates in the synthesis of prostaglandins 发明人:KERESZTES NEE ORDOG BORBALA; KOVACS GABOR; LOVASZ NEE GASPAR MARIANNA; REMPORT NEE RADOCZI JULIA; SIMONIDESZ VILMOS; STADLER ISTVAN; SZANTAY CSABA; SZEKELY ISTVAN; TOMOSKOZI ISTVAN; VISKY NEE GOMBOS ZSUZSA 权利人:CHINOIN GYOGYSZER ES VEGYESZET 摘要:A process for the preparation of optically active or racemic lactone diol derivatives of the formula (for use as intermediates in the Corey prostaglandin synthesis). Optically active or racemic lactone diol derivatives are inclosed, in which R3 and R4 are the same or different and stand for a hydrogen, or a lower alkanoyl optionally substituted with one, two or three halogen atoms, or form together a group, in which R5 and R6 are the same or different and stand for a hydrogen, alkyl or aryl, with a process for preparing them. According to the invention the above compound are prepared by reacting optically active or racemic lactone of the formula II with formaldehyde or with a formaldehyde polymerisate, in the presence of the mixture of a strong acid and water or of a lower alkane carboxylic acid optionally substituted with one, two or three halogen atoms, and then optionally subjecting the obtained compound of the general formula I, in which R3 and/or R4 stand for an alkanoyl optionally substituted with one, two or three halogen atoms to partial or total hydrolysis or alcoholysis in an acid or alkaline medium and/or reacting it with the oxo-compounds of the formula R5-CHO or R6-CO-R5 or with the acetals of the above compounds. The compounds according to the invention are useful intermediates in the Corey prostaglandine synthesis.
1: Jia Y, Liu LL, Su JL, Meng XH, Wang WX, Tian C. Effect of alprostadil in the treatment of intensive care unit patients with acute renal injury. World J Clin Cases. 2021 Feb 26;9(6):1284-1292. doi: 10.12998/wjcc.v9.i6.1284. 2: Wang M, Cai XF, Zhang SM, Xia SY, Du WH, Ma YL. Alprostadil alleviates liver injury in septic rats via TLR4/NF-κB pathway. Eur Rev Med Pharmacol Sci. 2021 Feb;25(3):1592-1599. doi: 10.26355/eurrev_202102_24869. 52(10):e13759. doi: 10.1111/and.13759. Epub 2020 Jul 21. 10(1):97-103. doi: 10.21037/apm-20-2147. 99(50):e23507. doi: 10.1097/MD.0000000000023507. 7: Shestakova KM, Moskaleva NE, Mesonzhnik NV, Kukharenko AV, Serkov IV, Lyubimov II, Fomina-Ageeva EV, Bezuglov VV, Akimov MG, Appolonova SA. In Vivo Targeted Metabolomic Profiling of Prostanit, a Novel Anti-PAD NO-Donating Alprostadil-Based Drug. Molecules. 2020 Dec 13;25(24):5896. doi: 10.3390/molecules25245896.
合成参考文献
参考文献:10.1073/pnas.94.2.746 摘要:Rossi A, Elia G, Santoro M . Inhibition of nuclear factor κB by prostaglandin A1: An effect associated with heat shock transcription factor activation. Proc. Natl. Acad. Sci. U.S.A. 1997 Jan 21;94(2):746–50. doi: 10.1073/pnas.94.2.746.